Vogliviga M 0.2 Forte Tablet contains Metformin 1000mg and Voglibose 0.2mg, a combination therapy for management of type 2 diabetes mellitus. It helps patients control blood sugar levels, particularly postprandial hyperglycemia, and supports overall glycemic balance.
Metformin reduces hepatic glucose production and improves insulin sensitivity, while Voglibose acts as an alpha-glucosidase inhibitor, delaying carbohydrate absorption from the intestine, thereby reducing post-meal blood glucose spikes.
Clinically, Vogliviga M 0.2 Forte Tablet is indicated for type 2 diabetes patients who require improved glycemic control, especially those with elevated postprandial glucose levels. The tablet formulation ensures accurate dosing, good absorption, and convenient oral administration, promoting adherence to therapy.
Regular use under medical supervision helps in maintaining blood sugar within target range, reducing the risk of diabetic complications, and improving overall metabolic control. Vogliviga M 0.2 Forte Tablet is a trusted anti-diabetic therapy, offering safe and effective management of type 2 diabetes mellitus.